News | May 03, 2021
Gujarat Themis Biosyn Q4FY21 net profit lower at Rs. 5.79 Cr
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
Gujarat Themis Biosyn has reported total income of Rs.93.82 crores for FY 2020-21
The Government of India has started importing the vital drug Remdesivir from other countries to ease out the shortage of Remdesivir in the country
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
Riding COVID-19 wave, Indian vaccine industry set to be Rs. 700 billion strong
The drug is approved for the treatment in metastatic colorectal carcinoma, metastatic breast cancer and ovarian, cervical and renal cancer
In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
This achievement enables the company to strengthen its presence in the high growth market of South Asian countries
Market penetration of Sputnik V will depend on competitive pricing, government orders and the ability to meet soaring demand through timely supply
The company also plans to register the similar range of products in the neighbouring countries.
Subscribe To Our Newsletter & Stay Updated
